Randox has announced that its fertility biochip array provides rapid and accurate diagnosis of disorders associated with the reproductive system.
The fertility biochip array allows simultaneous quantitative measurement of six fertility hormones from a single patient sample.
The Randox fertility array analyses hormones that regulate the reproductive cycle and is used to test for various associated conditions including infertility as well as non-reproductive disorders such as cancer.
The array includes estradiol, which is involved in the growth of the female reproductive organs and menstruation.
Estradiol is used to determine the cause of amenorrhea and to diagnose precocious puberty and gynecomastia.
Randox biochip array technology is based on Elisa principles and with as little as 75ul of serum all six parameters can be analysed at once.
Analytes include: FSH, LH, prolactin, progesterone, testosterone and estradiol.
Simultaneous analysis of six fertility hormones provides a comprehensive patient fertility profile, removing the need for expensive additional analyte testing.
Randox has developed the fully automated Evidence and the semi-automated Evidence Investigator systems for analysis of biochip arrays generating up to 378 fertility tests results per hour.
Implementation of these systems will provide laboratories with significant reductions in time and labour costs, according to the company.